{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Booth S"],"funding":["Cancer Research UK","University of Birmingham, University of Oxford, Blood Cancer UK","Blood Cancer UK","National Institute for Health Research (NIHR)"],"pagination":["892-901"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8652610"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["196(4)"],"pubmed_abstract":["Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·"],"journal":["British journal of haematology"],"pubmed_title":["Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy."],"pmcid":["PMC8652610"],"funding_grant_id":["30195","20011","CL-2018-18-002","ACF-2017-19-002","#20011"],"pubmed_authors":["Campton NA","Moody S","Innes A","Oram HS","Tillet T","Illingworth J","Arnold R","Newsom-Davies T","UKCCMP team","Curley HM","Middleton G","Wrench D","Collins GP","Apperly J","Cook LB","Dolly S","Rabin N","Cazier JB","Booth S","Pettengell R","Gault A","Tilby M","Lee LYW","Purshouse K","Aries J","Palles C","Altohami M","Cook G","Tomkins O","Kerr R","Mittal S","Mukherjee L","Varnai C","Kulasekararaj A","Ashcroft J","Carmichael J"],"additional_accession":[]},"is_claimable":false,"name":"Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.","description":"Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T22:43:32.376Z","creation":"2022-02-11T13:43:18.403Z"},"accession":"S-EPMC8652610","cross_references":{"pubmed":["34761389"],"doi":["10.1111/bjh.17937"]}}